Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ruxolitinib in anemic myelofibrosis patients
2016-003552-75Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in myelofibrosis (MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Novartis. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2016-003552-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003552-75.